What You Should Know:
– Know Labs (NYSE American: KNW), a leading innovator in non-invasive medical diagnostic technology, today announced the unveiling of its KnowU™, a wearable, non-invasive continuous glucose monitor (CGM).
– With over 270 patents issued, pending, and in process, Know Labs has established a solid foundation for its technology, creating a competitive advantage in the non-invasive CGM landscape.
Wearable, Non-invasive Continuous Glucose Monitor
Just eight months after announcing its initial prototype, Know Labs has significantly accelerated its development process to introduce the KnowU. This new iteration:
Incorporates the company’s proprietary sensor: This sensor has undergone successful lab testing for stability and accuracy and is now miniaturized and wearable.
Offers multiple wear options: Users can choose between an adhesive patch or a strap to wear the KnowU on their arm.
Enhances user experience: The device is significantly smaller and lighter than the prototype and boasts:
- Built-in computing power.
- Machine learning capabilities.
- Rechargeable battery.
- Easy-to-use companion mobile app.
Solid Scientific Foundation
KnowU is built upon Know Labs’ robust scientific foundation. The device utilizes a radiofrequency (RF) sensor with dielectric spectroscopy. This technology measures glucose levels by:
- Rapidly scanning a range of radio frequencies.
- Recording voltage values at each frequency.
- Employing proprietary machine learning algorithms to translate these values into real-time blood glucose levels.
“The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes,” said
Ron Erickson, CEO and Chairman at Know Labs. “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes. KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”